Evidence map›Paper›PMID 24910878›Full record

ReviewNanomedicine (London, England)2014

Bench-to-bedside translation of magnetic nanoparticles.

Dhirender Singh, JoEllyn M McMillan, Alexander V Kabanov, Marina Sokolsky-Papkov, Howard E Gendelman

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Pilot-scale production of expansile nanoparticles: Practical methods for clinical scale-up.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  8. Whither Magnetic Hyperthermia? A Tentative Roadmap.Materials (Basel, Switzerland) · 2021
    Article
  9. Article
  10. Article
  11. Stimuli-Responsive Materials for Tissue Engineering and Drug Delivery.International journal of molecular sciences · 2020
    Review
  12. Review
  13. Article
  14. Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dhirender Singh
JoEllyn M McMillan
Alexander V Kabanov
Marina Sokolsky-Papkov
Howard E Gendelman

Funding

Targeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ALNOUTI, YAZEN · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Proteomics CoreP01NS043985 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ZHENG, JIALIN CHARLES · 2003 to 2012
$11.8M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
SMART HANDR01AG043540 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, POLUEKTOVA, LARISA Y · 2013 to 2017
$3.1M
NEBRASKA CENTER FOR VIROLOGY: AIDSP30RR031151 · NCRR · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2010 to 2011
$2.9M
Blood Brain Barrier Physiology and HIV DementiaR37NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E. · 2001 to 2007
$2.7M
NCRR NIH HHS P30 RR031151NCRR NIH HHS P30RR031151NIA NIH HHS R01 AG043540NIDA NIH HHS 1P01DA028555NIDA NIH HHS P01 DA028555NIMH NIH HHS P01 MH064570NIMH NIH HHS P01MH64570NINDS NIH HHS 2R01NS034239NINDS NIH HHS 2R01NS36126NINDS NIH HHS P01 NS043985NINDS NIH HHS P01NS43985NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R37 NS036126
6 · The paper itself

Abstract

Magnetic nanoparticles (MNPs) are a new and promising addition to the spectrum of biomedicines. Their promise revolves around the broad versatility and biocompatibility of the MNPs and their unique physicochemical properties. Guided by applied external magnetic fields, MNPs represent a cutting-edge tool designed to improve diagnosis and therapy of a broad range of inflammatory, infectious, genetic and degenerative diseases. Magnetic hyperthermia, targeted drug and gene delivery, cell tracking, protein bioseparation and tissue engineering are but a few applications being developed for MNPs. MNPs toxicities linked to shape, size and surface chemistry are real and must be addressed before clinical use is realized. This article presents both the promise and perils of this new nanotechnology, with an eye towards opportunity in translational medical science.

Indexed as

AnimalsDrug Delivery SystemsHumansHyperthermia, InducedMagneticsMagnetite NanoparticlesNanomedicineTissue EngineeringTranslational Research, BiomedicalMagnetite Nanoparticles

Identifiers

PMID24910878
PMCPMC4150086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.